Raymond James Financial Services Advisors, Inc. Cyclacel Pharmaceuticals, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

  • $73.5 Billion
  • Q3 2024

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 25, 2022
SELL
$1.23 - $21.9 $12,300 - $219,000
-10,000 Reduced 32.46%
20,806 $30,000
Q2 2022

Aug 12, 2022
BUY
$6.1 - $7.15 $126,879 - $148,720
20,800 Added 207.88%
30,806 $33,000
Q1 2022

May 11, 2022
SELL
$5.93 - $7.6 $5,930 - $7,600
-1,000 Reduced 9.09%
10,006 $31,000
Q4 2021

Feb 08, 2022
BUY
$6.04 - $8.03 $6,040 - $8,029
1,000 Added 9.99%
11,006 $43,000
Q3 2021

Nov 02, 2021
SELL
$8.02 - $11.0 $401,000 - $550,000
-50,000 Reduced 83.33%
10,006 $53,000
Q2 2021

Aug 11, 2021
SELL
$7.59 - $10.48 $15,180 - $20,960
-2,000 Reduced 3.23%
60,006 $355,000
Q1 2021

May 14, 2021
BUY
$6.86 - $9.24 $34,300 - $46,200
5,000 Added 8.77%
62,006 $441,000
Q4 2020

Feb 12, 2021
BUY
$5.0 - $7.5 $56,250 - $84,375
11,250 Added 24.59%
57,006 $445,000
Q3 2020

Nov 04, 2020
BUY
$4.81 - $6.49 $72,150 - $97,350
15,000 Added 48.77%
45,756 $167,000
Q2 2020

Jul 17, 2020
BUY
$5.2 - $7.75 $159,931 - $238,359
30,756 New
30,756 $143,000

About Cyclacel Pharmaceuticals, Inc.

CYCC Quotes by TradingView
  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $7.9M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email